Natixis Rocket Pharmaceuticals, Inc. Transaction History

Natixis

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$15.07 - $24.05 $165 - $264	-11 Reduced 1.67%	649 $13,000
Q2 2023 Aug 11, 2023	SELL	$16.59 - $23.6 $564 - $802	-34 Reduced 4.9%	660 $13,000
Q4 2022 Feb 24, 2023	BUY	$15.5 - $22.76 $10,757 - $15,795	694 New	694 $13,000
Q1 2022 May 13, 2022	SELL	$13.16 - $23.68 $2.97 Million - $5.34 Million	-225,394 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$21.52 - $36.02 $4.85 Million - $8.12 Million	225,394 New	225,394 $4.92 Million

210

93.2M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $788M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.